LAB Q3 2024 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$388M

Q3 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$45M+77.3% YoY

Gross Profit

$23M51.7% margin

Operating Income

-$32M-70.5% margin

Net Income

-$27M-59.9% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+99.9%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$30M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$682M

Total Liabilities

$192M

Stockholders' Equity

$489M

Cash & Equivalents

$211M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$45M	$25M	+77.3%
Gross Profit	$23M	$11M	+108.5%
Operating Income	-$32M	-$21M	-49.8%
Net Income	-$27M	-$21M	-28.3%

Revenue Segments

Product And Service

$44M41%

Service

$24M23%

Product

$20M18%

Consumables

$14M13%

Instruments

$6M5%

Collaboration and Other Revenue

$938,0001%

Geographic Segments

Americas

$24M53%

EMEA

$16M36%

Asia Pacific

$5M11%